Contents:

Chapter 1: Executive Summary COPD Management COPD Therapeutics Pipeline Therapeutics The COPD Market Future Perspectives Chapter 2: COPD Definition and Symptoms Risk Factors Epidemiology Physiological Changes and COPD Underlying Molecular Mechanisms and COPD COPD Targets and Therapeutics Objectives and Scope Chapter 3: COPD Treatment Diagnosing COPD Current COPD Management Approaches Alternative Therapies and COPD Global Guidelines Educational Initiatives The Media Chapter 4: COPD Therapeutics Bronchodilators Anticholinergics ?-2 Agonists Methylxanthines Corticosteroids Alpha-1 Antitrypsin Augmentation Mucolytics Combination Therapies Drug Delivery Chapter 5: Lung Function Characteristic of COPD Targeting Bronchoconstriction Emerging Anticholinergics Emerging ?-2 Agonists Targeting Inflammation Targeting Inflammatory Mediators Targeting Cytokines Targeting Leukotrienes Targeting Phosphodiesterases Targeting Neutrophilic Inflammation Targeting Infection Targeting Proteases Targeting Elastase Targeting Alpha-1-antitrypsin Deficiency Targeting Matrix Metalloproteinases Targeting Signal Transduction Targeting Oxidants Targeting Airway Remodeling Targeting Mucus Hypersecretion Chapter 6: COPD in the Respiratory Market Market Size and Key Players Market Activity Big Pharma Small- to Medium-Sized Pharma and Biotech Diagnostics Drug Delivery Key Products Spiriva® Serevent® Advair® Symbicort®. Emerging Players Market Trends and Opportunities Chapter 7: Therapeutic and Market Potential of COPD Pipeline Drugs Therapeutic Potential Market Potential Pre-Market Pipeline COPD Diagnostics and Management COPD and Education COPD and Research Needs COPD and the Patient Summary Chapter 8: Expert Interviews Paolo Baroldi, VP Corporate Drug Development, Chiesi Pharmaceuticals Dr. Mary Fitzgerald, Executive Vice President (Respiratory), Argenta Discovery Richard Marsden, Managing Director, Synairgen plc Kevin Moulder, Domantis, Inc., Vice President, Development. Chapter 9: Company Profiles ALTANA Pharma AG Argenta Discovery Ltd Arriva Pharmaceuticals AstraZeneca plc Boehringer Ingelheim GmbH Chiesi Farmaceutici SpA DEY L.P Domantis elbion AG Epigenesis Pharmaceuticals Glenmark Pharmaceuticals Ltd GlaxoSmithKline plc Sepracor Synairgen plc Theravance Chapter 10: References Table of Exhibits Exhibit 2.1 Risk Factors and COPD Exhibit 2.2 Physiological Changes and COPD Exhibit 2.3 Immune Components Associated with COPD Exhibit 2.4 Emerging COPD Target Categories at GSK Exhibit 3.1 COPD and Asthma Differentiation Exhibit 3.2 Categorization of Severity of COPD Exhibit 3.3 Components of COPD Management Exhibit 3.4 GOLD Objectives Exhibit 3.5 Additions to GOLD Guidelines (2005) Exhibit 4.1 Approved Anticholinergics that Address COPD Exhibit 4.2 ?-2 Agonists Used to Treat COPD Exhibit 4.3 Inhaled Steroids Used for COPD Treatment Exhibit 4.4 Combination Therapies Used for COPD Treatment Exhibit 5.1 Pipeline GSK Compounds that Target Bronchoconstriction Exhibit 5.2 Emerging Anticholinergics Exhibit 5.3 Emerging Long-Acting ?-2 Agonists Exhibit 5.4 Pipeline PDE4 Inhibitors Indicated for COPD Exhibit 6.1 Companies Developing Products that Address COPD Exhibit 6.2 Recent Press Releases from Boehringer for Spiriva® Exhibit 6.3 Boehringer Products Relevant to COPD Exhibit 6.4 Revenues from Combination Therapies that Address COPD Exhibit 7.1 Launched COPD Drugs Exhibit 7.2 Pharmacology of COPD Pre-Approval Candidates Exhibit 7.3 Companies with COPD Candidates Exhibit 7.4 Compounds with Highest Novelty Rating Exhibit 7.5 EFA Goals Relating to COPD